78
Participants
Start Date
February 3, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2027
CMGV
"Initial treatment induction therapy: CMG+Vineclavone regimen Mitoxantrone liposomes 15mg/m2, iv, d1; Cytarabine 10mg/m2, H, q12h, d1-7; G-CSF starts at 5ug/kg, H, d0, WBC ≥ 30 × 109/L, stop G-CSF; Vinecla 100mg, 2200mg, 3400mg, d4-10. Every 4 weeks is a cycle, for a total of 2 cycles. For patients with CR/CRI/MLFS/PR in the first cycle, repeat this regimen for consolidation treatment once (the second course of treatment is Vineclavone 400mg d1-7).~Follow up treatment: Patients who meet the transplantation criteria will undergo hematopoietic stem cell transplantation, while those who do not undergo transplantation will continue to receive CMG+Vineclavone consolidation for 4-6 courses."
RECRUITING
Ruijin Hospital, Shanghai
Huadong Hospital
OTHER
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Huashan Hospital
OTHER
Army Medical Center of PLA
OTHER_GOV
Sun Yat-sen University
OTHER
RenJi Hospital
OTHER
Shanghai Jiading District Central Hospital
OTHER
The Second Affiliated Hospital of Dalian Medical University
OTHER
First Hospital of China Medical University
OTHER
Dalian Municipal Central Hospital
OTHER
Shanghai Zhongshan Hospital
OTHER
Shanghai Pudong Hospital
OTHER
Shanghai Public Health Clinical Center
OTHER_GOV
Xuhui Central Hospital, Shanghai
OTHER
The Affiliated People's Hospital of Ningbo University
OTHER_GOV
Taizhou First People's Hospital
OTHER
Wenzhou People's Hospital
OTHER
Ruijin Hospital
OTHER